Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials
Purpose:
To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A blockade, in patients with noninfectious uveitis.
Design:
Three multicenter, randomized, double-masked, placebo-controlled, dose-ranging phase III studies: SHIELD, INSURE, and ENDURE.
Participants:
A total of 118 patients with Behçet's uveitis (SHIELD study); 31 patients with active, noninfectious, non–Behçet's uveitis (INSURE study); and 125 patients with quiescent, noninfectious, non–Behçet's uveitis (ENDURE study) were enrolled.
Methods:
After an initial subcutaneous (s.c.) loading phase in each treatment arm, patients received s.c. maintenance therapy with (Read more...)